OptimizeRx (NASDAQ:OPRX) Given Market Outperform Rating at J

JMP Securities reissued their market outperform rating on shares of OptimizeRx (NASDAQ:OPRX – Free Report) in a research report released on Tuesday morning, Benzinga reports. The brokerage currently has a $15.00 price target on the stock. A number of other brokerages also recently commented on OPRX. Royal Bank of Canada reissued an outperform rating and […]

Related Keywords

Canada , Hong Kong , Stifel Nicolaus , Hong Kong Ltd , Charles Schwab Investment Management Inc , Royal Bank , Optimizerx Corporation , Nasdaq , Nuveen Asset Management , Barclays , Thrivent Financial For Lutherans , Free Report , Moderate Buy , Asset Management , Financial Advisors , Schwab Investment Management , Kong Ltd , Get Free Report , Evidence Based Physician Engagement , Care Banner , Optimizerx Daily , Optimizerx , Nasdaq Oprx , Oprx , Computer And Technology , Reiterated Rating , Jmp Securities ,